Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Abstract

Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, Supect®) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings. This review mainly focuses on the clinical potential of radotinib in patients with CML in chronic phase in terms of efficacy and safety.

• Authors: Ahmet Emre Eskazan, Dilek Keskin
• Journal: Therapeutic advances in hematology (Ther Adv Hematol) Vol. 8 Issue 9 Pg. 237-243 (Sep 2017) ISSN: 2040-6207 [Print] England
• PMID: 29051802 (Publication Type: Journal Article, Review)